EU action against  rare diseases
14 Sep 2018 – 16:21 | No Comment

Though individual rare diseases (RDs) affect less than five in every 10,000 people, the aggregate number of individuals suffering from a rare disease is estimated to be nearly 400 million worldwide. The lack of efficient …

Read the full story »
Health

Energy & Environment

Circular Economy

Climate Change

Security

Home » EU Health, Health, Policy

EU strengthens HTA cooperation among member states

Submitted by on 02 Feb 2018 – 12:55

Brussels has put the wheels in motion for better quality of care and innovative healthcare for the benefit of patients, especially those with unmet medical needs. The European  Commission has put forward a proposal to boost cooperation among member states for assessing health technology. Greater transparency will empower patients, by ensuring their access to information on the added clinical value of new technology that could potentially benefit them.

More assessments could lead to effective, innovative health tools reaching patients faster. For national authorities it means being able to formulate policies for their health systems based on more robust evidence.

300100_13sFurthermore, manufacturers will no longer have to adapt to different national procedures. Vice-President Katainen said: “Reinforcing Health Technology Assessment co-operation at EU level boosts innovation and improves competitiveness of the medical industry. The healthcare sector is a crucial part of our economy, it accounts for approximately 10% of the EU’s GDP. We are proposing a regulatory framework that will bring benefits to patients all over Europe, whilst encouraging innovation, helping the take-up of high-quality medtech innovations and improving the sustainability of health systems across the EU.”

Commissioner for Health and Food Safety, Vytenis Andriukaitis, said he expects this initiative to result in “a more efficient use of resources by member states through the pooling of resources and exchanges of expertise, thereby avoiding duplications in the assessment of the identical products.”